Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation


Autoria(s): Lima-Junior, Roberto Cesar P.; Figueiredo, Aline A.; Freitas, Helano C.; Melo, Maria Luisa P.; Wong, Deysi Viviana T.; Leite, Caio Abner V. G.; Medeiros, Raul P.; Marques-Neto, Raphael D.; Vale, Mariana L.; Brito, Gerly Anne C.; Oria, Reinaldo B.; Souza, Marcellus H. L. P.; Cunha, Fernando Q.; Ribeiro, Ronaldo A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

07/11/2013

07/11/2013

2012

Resumo

Purpose Intestinal mucositis and the closely associated diarrhea are common costly side effects of irinotecan. Cytokine modulators, such as thalidomide and pentoxifylline, are found capable of attenuating intestinal mucositis progression. Nitric oxide (NO) seems to be a key mediator of the antineoplastic drug toxicity. The aim of this study was to investigate the role of NO on the pathogenesis of intestinal mucositis, as well as the participation of cytokines upon inducible nitric oxide synthase (iNOS) expression in irinotecan-induced intestinal mucositis. Methods iNOS-knockout (iNOS(-/-)) and C57BL/6 (WT, wild type) animals (n = 5-6) were given either saline or irinotecan (60 mg/kg i.p for 4 days), with or without pretreatment with aminoguanidine (50 mg/kg s.c.), thalidomide (60 mg/kg s.c), infliximab (5 mg/kg i.v.), or pentoxifylline (1.7 mg/kg s.c). On day 5, diarrhea was assessed, and following euthanasia, proximal intestinal samples were obtained for myeloperoxidase (MPO) and iNOS activity, morphometric analysis, western blot and immunohistochemistry to iNOS, cytokine dosage, and for in vitro evaluation of gut contractility. Results Irinotecan induced severe diarrhea and intestinal smooth muscle over-contractility, accompanied with histopathological changes. Additionally, increased MPO and iNOS activity and iNOS immunoexpression were found in WT animals treated with irinotecan. The rise in MPO, smooth muscle over-contractility, and diarrhea were abrogated in aminoguanidine-treated and iNOS(-/-) mice. Moreover, through western blot, we verified that infliximab and pentoxifylline significantly inhibited irinotecan-induced iNOS expression. In addition, cytokine concentration was found only partially decreased in irinotecan-treated iNOS(-/-) mice when compared with wild-type animals that were given irinotecan. Conclusions This study suggests a role of nitric oxide in the pathogenesis of irinotecan-induced intestinal mucositis and also provides evidence for the participation of cytokines on iNOS induction.

CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)

CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)

FUNCAP (Fundacao Cearense de Apoio ao Desenvolvimento Cientifico)

Identificador

CANCER CHEMOTHERAPY AND PHARMACOLOGY, NEW YORK, v. 69, n. 4, pp. 931-942, APR, 2012

0344-5704

http://www.producao.usp.br/handle/BDPI/42909

10.1007/s00280-011-1780-z

http://dx.doi.org/10.1007/s00280-011-1780-z

Idioma(s)

eng

Publicador

SPRINGER

NEW YORK

Relação

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Direitos

closedAccess

Copyright SPRINGER

Palavras-Chave #IRINOTECAN #INTESTINAL MUCOSITIS #NITRIC OXIDE #CYTOKINES #NECROSIS-FACTOR-ALPHA #CLINICAL-PRACTICE GUIDELINES #EXPERIMENTAL ORAL MUCOSITIS #IN-VITRO #INHIBITORS PENTOXIFYLLINE #TNF-ALPHA #THALIDOMIDE #MICE #DAMAGE #CELLS #ONCOLOGY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion